Oncopeptides AB (STU:OND) Common Stock : €0.00 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Oncopeptides AB Common Stock?

Oncopeptides AB's annual common stock declined from Dec. 2022 (€0.95 Mil) to Dec. 2023 (€0.94 Mil) and declined from Dec. 2023 (€0.94 Mil) to Dec. 2024 (€0.00 Mil).

Oncopeptides AB Common Stock Historical Data

The historical data trend for Oncopeptides AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncopeptides AB Common Stock Chart

Oncopeptides AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

0.74

0.82

0.95

0.94

Oncopeptides AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial															0.94	-	-	-	-

Oncopeptides AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Oncopeptides AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (STU:OND) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden 0RN4:UK OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.